Glycolytic pathway enzyme in Leishmania species

Glycolytic pathway enzymes in Leishmania species comprise a set of essential enzymes responsible for the conversion of glucose to pyruvate through glycolysis, a process that is central for ATP production and survival of the parasite, particularly in its amastigote and promastigote life stages[1][2][5][8]. Many of these enzymes, such as hexokinase, phosphofructokinase, enolase, aldolase, and glucose-6-phosphate dehydrogenase, are compartmentalized within unique organelles (glycosomes) in trypanosomatids[1][5]. These enzymes are biologically essential, differentially regulated between lifecycle stages, and are involved in both energy generation and adaptation to stressful environments within the host[2][3][8]. Glycolytic enzymes, including those of the pentose phosphate pathway, have been validated as important therapeutic targets because they are required for parasite viability and are sufficiently divergent from human homologs to allow selective inhibition[1][5][7][9]. Inhibition of these enzymes (by drugs such as lonidamine or by oxidative stress-inducing agents like amphotericin B) leads to reduced parasite survival, impaired redox balance, and decreased infectivity. Some enzymes (e.g., enolase, aldolase) are also immunogenic and considered as possible biomarkers for infection or therapeutic response[3]. However, caution is needed in drug development due to the risk of host toxicity and the centrality of these enzymes to basic metabolism in both parasite and host[1][7].

Other names

Glycolysis enzyme in LeishmaniaLeishmania glycolytic enzymeLeishmania metabolic enzymeTrypanosomatid glycolytic enzyme

Inhibition of glycolytic enzyme catalytic activity (e.g., hexokinase, phosphofructokinase)[1][5]; Interference with energy metabolism via specific enzyme blockade; Indirect modulation of redox homeostasis (by impacting pentose phosphate pathway, e.g., G6PD inhibition)[7]; Increased oxidative stress as a consequence of redox imbalance